HK1151727A1 - Combination therapy with antibody drug conjugates - Google Patents

Combination therapy with antibody drug conjugates

Info

Publication number
HK1151727A1
HK1151727A1 HK11105912.1A HK11105912A HK1151727A1 HK 1151727 A1 HK1151727 A1 HK 1151727A1 HK 11105912 A HK11105912 A HK 11105912A HK 1151727 A1 HK1151727 A1 HK 1151727A1
Authority
HK
Hong Kong
Prior art keywords
combination therapy
drug conjugates
antibody drug
antibody
conjugates
Prior art date
Application number
HK11105912.1A
Other languages
English (en)
Chinese (zh)
Inventor
‧奧夫拉佐格魯
‧西弗斯
‧格伯
Original Assignee
西雅圖基因公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 西雅圖基因公司 filed Critical 西雅圖基因公司
Publication of HK1151727A1 publication Critical patent/HK1151727A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK11105912.1A 2007-10-12 2011-06-10 Combination therapy with antibody drug conjugates HK1151727A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97959407P 2007-10-12 2007-10-12
US2766808P 2008-02-11 2008-02-11
US4064108P 2008-03-28 2008-03-28
PCT/US2008/079224 WO2009048967A1 (en) 2007-10-12 2008-10-08 Combination therapy with antibody-drug conjugates

Publications (1)

Publication Number Publication Date
HK1151727A1 true HK1151727A1 (en) 2012-02-10

Family

ID=40549535

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11105912.1A HK1151727A1 (en) 2007-10-12 2011-06-10 Combination therapy with antibody drug conjugates

Country Status (14)

Country Link
US (2) US8263083B2 (ja)
EP (1) EP2211885B1 (ja)
JP (1) JP5485897B2 (ja)
KR (1) KR101641345B1 (ja)
CN (1) CN101969970B (ja)
AU (1) AU2008310908B2 (ja)
CA (1) CA2699090C (ja)
EA (1) EA020696B1 (ja)
HK (1) HK1151727A1 (ja)
IL (1) IL204851A (ja)
MX (1) MX2010003977A (ja)
NZ (1) NZ584552A (ja)
WO (1) WO2009048967A1 (ja)
ZA (1) ZA201002428B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
AU2008276128B2 (en) 2007-07-16 2013-10-10 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
ES2381788T3 (es) 2007-07-16 2012-05-31 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
CN101969970B (zh) 2007-10-12 2014-10-15 西雅图基因公司 用抗体-药物偶联物联合治疗
IL287292B (en) 2008-01-31 2022-09-01 Genentech Inc and fusion antibody-drug-cd79b engineered antibodies cysteine-
CA2749115C (en) 2009-01-09 2022-06-21 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
US8758758B1 (en) * 2010-01-08 2014-06-24 Seattle Genetics, Inc. Post-relapse treatment of CD30 expressing lymphomas
EP3395361A1 (en) * 2010-02-08 2018-10-31 Agensys, Inc. Antibody drug conjugates (adc) that bind to 161p2f10b proteins
EA201790850A1 (ru) * 2010-09-29 2017-11-30 Эдженсис, Инк. Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12
CN106563128B (zh) 2010-10-22 2020-05-22 西雅图遗传学公司 以奥里斯他汀为主的抗体药物结合物和结合mTOR的抑制剂在制备治疗癌症药物中的用途
US9958455B2 (en) * 2011-09-29 2018-05-01 Seattle Genetics, Inc. Intact mass determination of protein conjugated agent compounds
KR101961976B1 (ko) * 2011-10-14 2019-03-25 시애틀 지네틱스, 인크. 피롤로벤조디아제핀 및 표적 접합체
MY168297A (en) 2011-11-17 2018-10-23 Pfizer Cytotoxic Peptides and Antibody Drug Conjugates Thereof
ES2725569T3 (es) * 2012-02-10 2019-09-24 Seattle Genetics Inc Diagnóstico y tratamiento de cánceres que expresan CD30
WO2014072897A1 (en) 2012-11-07 2014-05-15 Pfizer Inc. Anti-notch3 antibodies and antibody-drug conjugates
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
RS60349B8 (sr) 2014-09-23 2022-10-31 Hoffmann La Roche Postupak upotrebe anti-cd79b imunokonjugata
BR112017011111A2 (pt) 2014-11-25 2017-12-26 Adc Therapeutics Sa conjugados de pirrolobenzodiazepina-anticorpo
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
KR20200066676A (ko) * 2017-10-11 2020-06-10 시애틀 지네틱스, 인크. 항-cd30 항체 약물 콘주게이트 요법의 부작용을 감소시키는 방법
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
SG11202002697WA (en) * 2017-10-13 2020-04-29 Seattle Genetics Inc Modulating the immune response using antibody-drug conjugates
IL277748B1 (en) * 2018-04-06 2024-03-01 Seagen Inc Camptothecin peptide conjugates
WO2020127618A1 (en) * 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
KR20220079606A (ko) * 2019-10-04 2022-06-13 씨젠 인크. 캄프토테신 펩티드 접합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20070134243A1 (en) * 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
WO2007011968A2 (en) * 2005-07-18 2007-01-25 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
AU2006302254B2 (en) * 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
US8257706B2 (en) * 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
WO2008103916A2 (en) 2007-02-23 2008-08-28 The Trustees Of Columbia Univeristy In The City Of New York Compositions and methods for treating cancer or a neurotrophic disorder
CN101969970B (zh) 2007-10-12 2014-10-15 西雅图基因公司 用抗体-药物偶联物联合治疗

Also Published As

Publication number Publication date
EA020696B1 (ru) 2015-01-30
WO2009048967A1 (en) 2009-04-16
NZ584552A (en) 2012-07-27
US20100215671A1 (en) 2010-08-26
US8470329B2 (en) 2013-06-25
CA2699090C (en) 2016-02-02
KR20100087288A (ko) 2010-08-04
CN101969970A (zh) 2011-02-09
EP2211885B1 (en) 2015-07-29
CA2699090A1 (en) 2009-04-16
EP2211885A1 (en) 2010-08-04
US20130022627A1 (en) 2013-01-24
US8263083B2 (en) 2012-09-11
JP2011500582A (ja) 2011-01-06
CN101969970B (zh) 2014-10-15
AU2008310908B2 (en) 2014-01-09
MX2010003977A (es) 2010-04-30
EA201070463A1 (ru) 2010-10-29
JP5485897B2 (ja) 2014-05-07
ZA201002428B (en) 2011-06-29
IL204851A0 (en) 2010-11-30
IL204851A (en) 2016-08-31
EP2211885A4 (en) 2012-09-26
KR101641345B1 (ko) 2016-07-20
AU2008310908A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
HK1151727A1 (en) Combination therapy with antibody drug conjugates
HK1207976A1 (en) Auristatin drug linker conjugates
EP1912671A4 (en) BETA-glucuronide LINKER ARZNEIKONJUGATE
ZA201006763B (en) Drug fusions and conjugates
ZA201001442B (en) Combination therapy with type i and type ii anti-cd20 antibodies
EP2109625A4 (en) USE OF ANTIBODY CONJUGATES
EP2253348A4 (en) DEVICE FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
EP2190853A4 (en) HALOGENIDE-FREE COMPLEXES FROM GLUCOSAMINE AND AN ACIDIC ACID
IL197316A0 (en) Buprenophine-wafer for drug substitution therapy
ZA201201218B (en) 3-polylysine conjugates and the use thereof
IL199992A0 (en) Combination therapy
EP1841467A4 (en) COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES
EP2054061A4 (en) COMBINATION THERAPY
ZA200806318B (en) Drug combinations
GB0719518D0 (en) Therapy
ZA201003729B (en) Conjugates of anti-rg-1 antibodies
GB0815788D0 (en) Therapeutic antibodies
IL197883A0 (en) Combination drug
GB0700773D0 (en) Drug therapies
EP2076239A4 (en) COMBINATION THERAPY
GB0600528D0 (en) Drug detector
EP2211863A4 (en) COMBINATION THERAPY
IL199718A0 (en) Peptide-complement conjugates
EP2324059A4 (en) THERAPEUTIC ANTI-PAMP ANTIBODIES
GB0700284D0 (en) Combination therapy